0001172661-25-002448.txt : 20250620 0001172661-25-002448.hdr.sgml : 20250620 20250620162340 ACCESSION NUMBER: 0001172661-25-002448 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250620 DATE AS OF CHANGE: 20250620 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Jade Biosciences, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-92668 FILM NUMBER: 251061698 BUSINESS ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: (781) 312-3013 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aerovate Therapeutics, Inc. DATE OF NAME CHANGE: 20200103 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Deep Track Capital, LP CENTRAL INDEX KEY: 0001856083 ORGANIZATION NAME: EIN: 853360885 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: 200 GREENWICH AVENUE STREET 2: 3RD FLOOR CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 2034090812 MAIL ADDRESS: STREET 1: 200 GREENWICH AVENUE STREET 2: 3RD FLOOR CITY: GREENWICH STATE: CT ZIP: 06830 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001856083 XXXXXXXX LIVE Common Stock, $0.0001 par value per share 04/28/2025 0001798749 Jade Biosciences, Inc. 008064206 221 Crescent St. Building 23, Suite 105 WALTHAM MA 02453 Rule 13d-1(c) Deep Track Capital, LP b DE 0.00 2784648.00 0.00 2784648.00 2784648.00 N 8.64 IA OO Deep Track Biotechnology Master Fund, Ltd. b E9 0.00 2784648.00 0.00 2784648.00 2784648.00 N 8.64 CO David Kroin b X1 0.00 2784648.00 0.00 2784648.00 2784648.00 N 8.64 HC IN Jade Biosciences, Inc. 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453 (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (i) Delaware (ii) Cayman Islands (iii) United States Y 2,784,648 8.64% 0 2,784,648 0 2,784,648 Y Y N Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of June 20, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person The amount beneficially owned by each Reporting Person is determined based on 32,235,926 Common Stock outstanding as of April 28, 2025, according to the issuer's 8-K filed with the SEC on May 1, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: June 20, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Capital, LP /s/ David Kroin 06/20/2025 Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin 06/20/2025 David Kroin /s/ David Kroin 06/20/2025